Please login to the form below

Not currently logged in
Email:
Password:

pancreatic adenocarcinoma.

This page shows the latest pancreatic adenocarcinoma. news and features for those working in and with pharma, biotech and healthcare.

Merus makes case for bispecific antibody in specific cancer gene fusion

Merus makes case for bispecific antibody in specific cancer gene fusion

assessment. The three patients are currently remaining on treatment. The data also showed that the experimental therapy worked across cancer types – patient one and two had pancreatic ductal adenocarcinoma, with the ... It is notable that two of the

Latest news

  • EU green light for Novartis' skin cancer therapy EU green light for Novartis' skin cancer therapy

    Other studies of the drug are ongoing in prostate cancer, pancreatic adenocarcinoma, ovarian cancer, non-small cell lung cancer and triple-negative breast cancer, as well as haematological malignancies such as

  • BMS and Celgene to research cancer immunotherapy combo BMS and Celgene to research cancer immunotherapy combo

    Positive study results would also benefit Celgene, which currently markets Abraxane as a treatment for pancreatic cancer and metastatic breast cancer. ... pancreatic adenocarcinoma will be treated with Abraxane, gemcitabine and Opdivo.

  • Merck KGaA starts third phase III trial for cancer hope TH-302 Merck KGaA starts third phase III trial for cancer hope TH-302

    Merck KGaA has started a phase III trial of its novel cancer candidate TH-302 in patients with locally advanced or metastatic pancreatic adenocarcinoma. ... The new phase III trial -called MAESTRO - aims to enrol 600 patients and will compare TH-302 plus

  • RNA interference rebirth RNA interference rebirth

    pancreatic adenocarcinoma. I. ALN-VSP. Alnylam. VEGF/KSP. liver cancers. I. ALN-TTR. Alnylam.

More from news
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest from PMHub

  • Enablers of drug innovation could lie in the numbers

    Take the pancreatic adenocarcinoma scenario for example, if the drug developers had targeted their research in Europe instead of the USA, one could have found a much more favourable research environment. ... 7)  EpiomicTM Patient Segmentation Database,

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

OPEN Health delivers over 250 virtual activities during COVID-19 – A clear path forward
...
Can eLearning improve patient recruitment and retention?
Some patients will still want to read pages of informed consent forms before joining a clinical trial, or want timely updates on paper rather than a notification on their phone....
How Far Do You Want To Go?
Join OPEN Health's virtual careers event on Tuesday 10th November, 15:00–17:00 GMT and discover where a career in medical communications could take you…...

Infographics